High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2023 Jan 13

PMID 36636625

Authors

Xuegang Wang

Weiquan Li

Ning Lou

Weiwei Han

Bo Hai

Wen Xiao

Xiaoping Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Invasion and metastasis led to poor prognosis and death of clear cell renal cell carcinoma (ccRCC) patients. The deoxynucleotidyl transferase terminal interacting protein 1 (DNTTIP1) was reported to promote multiple tumor progression. However, there is no research about DNTTIP1 in ccRCC.

Methods: Kaplan-Meier survival analysis, multivariate analysis demonstrated the prognostic indicator in overall survival (OS) and disease-free survival (DFS) of ccRCC with DNTTIP1 expression in the Cancer Genome Atlas Kidney Clear Cell Carcinoma (TCGA-KIRC). Receiver operator characteristic (ROC) curve analyzed diagnostic ability of DNTTIP1 in TCGA-KIRC and validation dataset. The quantitative real-time polymerase chain reaction (qRT-PCR) detected the DNTTIP1 expression in renal cancer tissues, and the Office of Cancer Clinical Proteomics Research (CPTAC) verified the protein expression of DNTTIP1. Moreover, nomogram predicted the role of DNTTIP1 in ccRCC patient. Single-sample Gene Set Enrichment Analysis (SsGSEA) and GSEA evaluated the pathogenesis role of DNTTIP1 in TCGA-KIRC.

Results: DNTTIP1 expression was higher in ccRCC tumor tissues. High expression of DNTTIP1 was associated with poor OS (HR = 1.618, P < 0.0001), and poor DFS (HR = 1.789, P < 0.0001). SsGSEA and GSEA showed DNTTIP1 was associated with hypoxia, epithelial-mesenchymal transition (EMT), angiogenesis, G2M checkpoint. DNTTIP1 had a positive correlation with EMT biomarkers in ccRCC, and might be an effective target for ccRCC.

Conclusion: This study provided that higher expression of DNTTIP1 predicted poor prognosis in ccRCC, and DNTTIP1 might be a novel detection biomarker and therapeutic target of tumor malignant in the future.

Citing Articles

Emerging role of exosomes in cancer therapy: progress and challenges.

Li J, Wang J, Chen Z Mol Cancer. 2025; 24(1):13.

PMID: 39806451 PMC: 11727182. DOI: 10.1186/s12943-024-02215-4.

Prognostic Value and Immunological Role of POP7 in Clear Cell Renal Cell Carcinoma.

Lou N, Meng X, Yu T, Li W, Lv X, Han W Pharmgenomics Pers Med. 2024; 17:521-534.

PMID: 39620194 PMC: 11608043. DOI: 10.2147/PGPM.S469247.

Exosome in renal cell carcinoma progression and implications for targeted therapy.

Li X, Xiao W, Yang H, Zhang X Front Oncol. 2024; 14:1458616.

PMID: 39296981 PMC: 11408481. DOI: 10.3389/fonc.2024.1458616.

References

Feng D, Zhang F, Liu L, Xiong Q, Xu H, Wei W . SKA3 Serves as a Biomarker for Poor Prognosis in Kidney Renal Papillary Cell Carcinoma. Int J Gen Med. 2021; 14:8591-8602. PMC: 8627265. DOI: 10.2147/IJGM.S336799. View

He K, Xie M, Li J, He Y, Yin Y . CENPO is Associated with Immune Cell Infiltration and is a Potential Diagnostic and Prognostic Marker for Hepatocellular Carcinoma. Int J Gen Med. 2022; 15:7493-7510. PMC: 9521242. DOI: 10.2147/IJGM.S382234. View

Dong Z, Gao M, Li C, Xu M, Liu S . LncRNA UCA1 Antagonizes Arsenic-Induced Cell Cycle Arrest through Destabilizing EZH2 and Facilitating NFATc2 Expression. Adv Sci (Weinh). 2020; 7(11):1903630. PMC: 7284218. DOI: 10.1002/advs.201903630. View

Meng X, Yuan H, Li W, Xiao W, Zhang X . Biomarker Screening and Prognostic Significance Analysis for Renal Cell Carcinoma. Int J Gen Med. 2021; 14:5255-5267. PMC: 8434883. DOI: 10.2147/IJGM.S325347. View

Xiong Z, Xiong W, Xiao W, Yuan C, Shi J, Huang Y . NNT-induced tumor cell "slimming" reverses the pro-carcinogenesis effect of HIF2a in tumors. Clin Transl Med. 2021; 11(1):e264. PMC: 7803359. DOI: 10.1002/ctm2.264. View

Yin L, Li W, Xu A, Shi H, Wang K, Yang H . SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway. EBioMedicine. 2020; 51:102596. PMC: 7000347. DOI: 10.1016/j.ebiom.2019.12.005. View

Chen B, Zhang G, Lai J, Xiao W, Li X, Li C . Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine. 2021; 71:103542. PMC: 8399410. DOI: 10.1016/j.ebiom.2021.103542. View

Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M . Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res. 2010; 70(23):9659-70. DOI: 10.1158/0008-5472.CAN-10-2034. View

Li W, Meng X, Yuan H, Xiao W, Zhang X . M2-polarization-related CNTNAP1 gene might be a novel immunotherapeutic target and biomarker for clear cell renal cell carcinoma. IUBMB Life. 2022; 74(5):391-407. DOI: 10.1002/iub.2596. View

10.

. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499(7456):43-9. PMC: 3771322. DOI: 10.1038/nature12222. View

11.

Lainakis G, Bamias A . Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets. 2008; 8(5):349-58. DOI: 10.2174/156800908785133132. View

12.

Li Y, Wu M, Zhang L, Wan L, Li H, Zhang L . Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner. Cell Death Discov. 2022; 8(1):402. PMC: 9525646. DOI: 10.1038/s41420-022-01190-3. View

13.

Bao Z, Cheng J, Zhu J, Ji S, Gu K, Zhao Y . Using Weighted Gene Co-Expression Network Analysis to Identify Increased MND1 Expression as a Predictor of Poor Breast Cancer Survival. Int J Gen Med. 2022; 15:4959-4974. PMC: 9117423. DOI: 10.2147/IJGM.S354826. View

14.

Zhuang H, Chen Y, Sheng X, Hong L, Gao R, Zhuang X . Searching for a signature involving 10 genes to predict the survival of patients with acute myelocytic leukemia through a combined multi-omics analysis. PeerJ. 2020; 8:e9437. PMC: 7321666. DOI: 10.7717/peerj.9437. View

15.

Gu W, Gong L, Wu X, Yao X . Hypoxic TAM-derived exosomal miR-155-5p promotes RCC progression through HuR-dependent IGF1R/AKT/PI3K pathway. Cell Death Discov. 2021; 7(1):147. PMC: 8206073. DOI: 10.1038/s41420-021-00525-w. View

16.

Schodel J, Grampp S, Maher E, Moch H, Ratcliffe P, Russo P . Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. Eur Urol. 2015; 69(4):646-657. PMC: 5012644. DOI: 10.1016/j.eururo.2015.08.007. View

17.

Ravaud A, Motzer R, Pandha H, George D, Pantuck A, Patel A . Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016; 375(23):2246-2254. DOI: 10.1056/NEJMoa1611406. View

18.

Chorzalska A, Ahsan N, Rao R, Roder K, Yu X, Morgan J . Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. Mol Oncol. 2018; 12(5):630-647. PMC: 5928369. DOI: 10.1002/1878-0261.12186. View

19.

Qiu B, Ackerman D, Sanchez D, Li B, Ochocki J, Grazioli A . HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2015; 5(6):652-67. PMC: 4456212. DOI: 10.1158/2159-8290.CD-14-1507. View

20.

Chen W, Hill H, Christie A, Kim M, Holloman E, Pavia-Jimenez A . Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016; 539(7627):112-117. PMC: 5340502. DOI: 10.1038/nature19796. View